TRIPS-plus

TRIPS-plus refers to intellectual property (IP) protection standards that exceed the minimum requirements set by the World Trade Organization's (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). These heightened standards are typically found in bilateral or regional free trade agreements (FTAs). Key examples include extending patent terms beyond the standard 20 years, mandating data exclusivity for pharmaceutical clinical trial data, and implementing patent linkage systems. While not a single codified standard like an ISO norm, its provisions are detailed in agreements such as the USMCA. In enterprise risk management, TRIPS-plus constitutes a significant regulatory and market risk, directly impacting R&D strategy, product launch timelines, and competitive landscapes, especially for IP-intensive industries like pharmaceuticals and biotechnology.

Applying TRIPS-plus in risk management involves three key steps. First, 'Regulatory Monitoring and Impact Analysis': systematically tracking trade negotiations in key markets and quantifying the financial impact of potential TRIPS-plus provisions on product pipelines, such as delayed generic drug entry. Second, 'IP Portfolio Strategy Adjustment': re-aligning patent strategies based on risk analysis, such as pursuing 'design-around' innovations or secondary patents in high-risk jurisdictions. Third, 'Supply Chain and Market Diversification': reducing dependency on markets with stringent TRIPS-plus rules by expanding into regions with more policy flexibility. A measurable outcome would be to decrease revenue reliance on high-risk markets by a set percentage, thereby improving overall business resilience and achieving a higher audit pass rate for regulatory compliance.

Taiwanese enterprises face three primary challenges with TRIPS-plus. First, 'Unequal Bargaining Power' in trade negotiations often forces acceptance of stringent IP terms. The solution is for industry associations to provide data-driven impact assessments to government negotiators. Second, 'Resource Constraints for SMEs', as smaller biotech and tech firms lack the budget for complex international IP legal counsel. A shared legal resource platform or government subsidy can mitigate this. Third, 'Constraints on Innovation Models', as TRIPS-plus measures like data exclusivity hinder the 'me-too' or generic drug strategies common among Taiwanese firms. The counter-strategy is to pivot R&D towards niche innovations or biosimilars, setting clear targets to increase the portfolio percentage of such projects.

Winners Consulting specializes in TRIPS-plus for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact